Posts tagged opioids
Tetra readies Phase 3 pain relief trial of medical cannabis

Tetra Bio-Pharma (CSE:TBP; OTCQB:TBPMF) and subsidiary, PhytoPain Pharma, have submitted a report on the safety and pharmacokinetics of its PPP001 smokeable cannabis product to Health Canada.

Read More
HCW starts Trevena at buy

H.C. Wainwright initiated coverage of Trevena (NASDAQ:TRVN) with a “buy” rating and $11 price target. The shares were changing hands at $6.85 at mid-day on Jan. 9.

Read More
Braeburn presents Probuphine data at CPDD meeting

Closely-held Braeburn Pharmaceuticals has presented data from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine implant for the long-term maintenance treatment of opioid dependence, at the annual scientific meeting of The College on Problems of Drug Dependence (CPDD).

The FDA recently approved Probuphine, which was developed by its partner, Titan Pharmaceuticals (NASDAQ:TTNP), on May 26.

Read More
Titan Pharma presents Phase 3 Probuphine data

Titan Pharmaceuticals (NASDAQ:TTNP) has presented data from the last Phase 3 study of Probuphine, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster session during the 47th Annual American Society of Addiction Medicine Annual Conference.

The data indicate that participants who were clinically stable on sublingual buprenorphine at a dose of 8 mg or less per day maintained stability when transferred to Probuphine, and that they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine.

Read More
Leerink starts Depomed at outperform

Leerink Partners has initiated coverage of Depomed (NASDAQ:DEPO) with an “outperform” rating and $21 price target. The stock closed at $14.62 on Wednesday.

“Depomed’s Nucynta for chronic pain provides a differentiated and durable growth asset, and we expect shares to appreciate over the next 12 months, driven by a Nucynta patent settlement and continued acceleration of script trends,” writes analyst Jason Gerberry.

Read More